Company News

KLUS Pharma will attend 2023 Bio-Europe Spring live and virtual partnering events.

Merck and Kelun-Biotech announced that the companies have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer.

A scientific poster of SKB264 will be presented at 2022 SABCS highlighting key data from Phase 2 TNBC study.

Come meet with us at BIO Partnering at JPM 2023 to learn more about our innovative pipeline!

KLUS Pharma is Attending BioPharm America in Boston from September 28-29

Kelun-Biotech Announces Oncology Research Collaboration and License Agreement with MSD

Kelun-Biotech's small molecule A400/EP0031 obtained IND approval from the FDA submitted by collaboration partner Ellipses Pharma

Clinical updates will be presented at 2022 ASCO for the Phase 1 dose-expansion study of A166 in HER2+ metastatic breast cancer.

KLUS Pharma will attend 2022 BIO International in San Diego from June 13-16.

KLUS Pharma will attend BIO-Europe Spring to be held virtually from March 28-31, 2022.

KLUS Pharma will attend the 40th Annual J.P. Morgan Health Care Conference to be held virtually from January 10-13, 2022

Kelun-Biotech will present an oral update on SKB264 at 2021 ESMO Annual Meeting held from September 16-21.